Contribution by NRF2 Upregulation to Lung Carcinogenesis and the Possible Therapeutic Value of NRF2 Inhibition by GSK-3 (Joint with Universities of St Andrews, Edinburgh and Pennsylvania)

StatusActive
Effective start/end date1/05/1631/10/19

Funding

  • Medical Research Council (MR/N009851/1): £854,266.00